Abstract
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have